| Abstrakt: |
A recent study conducted by the Clinical Pharmacology Group has revealed new findings on hypertension. The researchers focused on the dysregulation of the hormone aldosterone as a cause of hypertension. They found that lorundrostat, a highly selective inhibitor of aldosterone synthase, showed promising results in reducing plasma aldosterone levels in healthy participants. The study also demonstrated a favorable safety profile for lorundrostat, with minimal effects on cortisol production and serum potassium levels. These findings suggest that lorundrostat could be a potential treatment for aldosterone-dependent, uncontrolled hypertension. [Extracted from the article] |
